A study by AXIM Biotechnologies, a global leader in cannabinoid research and maker of CanChew Plus CBD Gum, found that 30 mg doses of cannabidiol (CBD) helped alleviate irritable bowel syndrome (IBS) symptoms in patients, according to a news release.
“These results show that excellent bioavailability for CBD may be achieved via our proprietary chewing gum delivery system, so that patients suffering from IBS may have symptomatic relief using an easy-to-use solution,” said CEO of AXIM Biotech George E. Anastassov.
The company will begin a clinical trial of its hemp-derived CanChew Plus gum — which it claims provides a stronger bioavailability than smoking or oral intake — in the near future.
AXIM Biotech already has a medicinal cannabis-based gum on the market: CanChew. According to the company news release, the mint-flavored gum is non-habit forming, does not require a prescription and is available nationwide. AXIM Biotech claims CanChew Plus